ALLOPURINOL

Course overview

ALLOPURINOL, A XANTHINE OXIDASE INHIBITOR, IS A URATE-LOWERING MEDICATION THAT IS FDA APPROVED FOR MANAGING GOUT, PREVENTING TUMOR LYSIS SYNDROME, AND PREVENTING RECURRENT CALCIUM NEPHROLITHIASIS IN PATIENTS WITH HYPERURICOSURIA. OTHER NON-FDA-APPROVED INDICATIONS INCLUDE LESCH-NYHAN SYNDROME-ASSOCIATED HYPERURICEMIA AND THE PREVENTION OF RECURRENT URIC ACID NEPHROLITHIASIS. IT IS IMPORTANT TO NOTE THAT ASYMPTOMATIC HYPERURICEMIA IS NOT AN INDICATION OF ALLOPURINOL OR ANY URATE-LOWERING THERAPY. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM, PHARMACOLOGY, CONTRAINDICATIONS, AND ADVERSE EVENTS ASSOCIATED WITH ALLOPURINOL DRUG THERAPY.